Positive Results in Cancer Vaccine Trial for Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Morphogenesis, Inc., a biotechnology company focused on developing cancer vaccines, in partnership with CohBar, believes they have met their milestone with IFx-HU2.0, a cancer vaccine studied in advanced Merkel cell carcinoma and squamous cell carcinoma. The intent is to overcome resistance to current immunotherapies.

A poster presentation at the 2023 Annual ASCO Meeting in Chicago revealed that five out of seven patients (71%) managed durable responses after IFx-HU2.0 (IFx) therapy. The patients were dosed at three different levels and were successfully rechallenged where they had previously shown resistance. They exhibited a promising safety profile at all three dosing levels.

Dr. James Bianco, Morphogenesis CEO, commented that four out of five (80%) of patients received long-lasting responses. The company is a UF startup and a graduate of UF Innovate | Accelerate at Sid Martin Biotech.

Read more about Positive Results in Cancer Vaccine Trial for Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma.